Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14997582 | 0.97 | TSHR (0.53) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL14997583 | 0.97 | TSHR (0.53) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL7898330 | 0.94 | MEN1 (0.65) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL11954753 | 0.94 | MEN1 (0.65) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL26397994 | 0.94 | MEN1 (0.65) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL26474467 | 0.91 | MEN1 (0.61) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL15463146 | 0.88 | TSHR (0.50) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL3841379 | 0.88 | TSHR (0.50) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL25885638 | 0.88 | TSHR (0.50) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL24052896 | 0.87 | MEN1 (0.55) | TSHRMAPK1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3707193-A1 | DENDRIMER DELIVERY SYSTEM AND METHODS OF USE THEREOF | The Johns Hopkins University (US) | 2020-09-16 | — | — | EP | claimed |
| US-20190142964-A1 | DENDRIMER DELIVERY SYSTEM AND METHODS OF USE THEREOF | Ashvattha Therapeutics, Inc. | 2019-05-16 | — | — | US | claimed |
| US-20260102502-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | UNIV JOHNS HOPKINS (US) | 2026-04-16 | — | — | US | disclosed |
| US-20250352653-A1 | NEURON TARGETED 2-DEOXYGLUCOSE DENDRIMER FOR IMAGING AND TREATMENT OF NEUROLOGICAL DISEASES | UNIV WASHINGTON STATE (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250269044-A1 | PSMA-TARGETED DENDRIMER NANOPLATFORM FOR CANCER DETECTION AND THERAPY | WASHINGTON STATE UNIVERSITY | 2025-08-28 | — | — | US | disclosed |
| EP-4577246-A1 | DENDRIMER CONJUGATES OF ANTIDEPRESSANT AND ANTIPSYCHOTIC AGENTS AND THEIR METHODS OF USE | The Johns Hopkins University (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4577245-A1 | DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF PSYCHEDELIC THERAPEUTICS | The Johns Hopkins University (US) | 2025-07-02 | — | — | EP | disclosed |
| EP-4577247-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | The Johns Hopkins University (US) | 2025-07-02 | — | — | EP | disclosed |
| WO-2025137151-A2 | DENDRIMER COMPOSITIONS FOR THE TREATMENT OF ATHEROSCLEROSIS, OBESITY, AND METABOLIC SYNDROMES | THE JOHNS HOPKINS UNIVERSITY (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250195672-A1 | DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTICS TO NEURONS | THE JOHNS HOPKINS UNIVERSITY | 2025-06-19 | — | — | US | disclosed |
| EP-4504268-A1 | DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTICS TO NEURONS | The Johns Hopkins University (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20080290034-A1 | Bridged macrocyclic module compositions | COVALENT PARTNERS LLC | 2008-11-27 | — | — | US | disclosed |
| US-20080290034-A1 | Bridged macrocyclic module compositions | COVALENT PARTNERS LLC | 2008-11-27 | — | — | US | disclosed |
| US-7368564-B2 | Bridged macrocyclic module compositions | COVALENT PARTNERS, LLC (US) | 2008-05-06 | — | — | US | disclosed |
| US-7368564-B2 | Bridged macrocyclic module compositions | COVALENT PARTNERS, LLC (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080039547-A1 | Moisture activated latent curing adhesive or sealant | ETHICON, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039548-A1 | Moisture activated latent curing adhesive or sealant | ETHICON, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20070293569-A1 | Pentaerythritol Derivatives and a Method for Preparation Thereof, and Liquid Crystal Base Containing the Same | AMOREPACIFIC CORPORATION | 2007-12-20 | — | — | US | disclosed |
| US-20070059563-A1 | Magnetic recording medium | FUJI PHOTO FILM CO., LTD. | 2007-03-15 | — | — | US | disclosed |
| US-20070059563-A1 | Magnetic recording medium | FUJI PHOTO FILM CO., LTD. | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039548-A1 | Moisture activated latent curing adhesive or sealant | ICAM1, EHMT1, CDH1 | TSHR 4861/4885MAPK1 2967/4885MEN1 1948/4885 |
| US-20070293569-A1 | Pentaerythritol Derivatives and a Method for Preparation Thereof, and Liquid Crystal Base Containing the Same | ELOVL1, SQLE, MSMO1 | TSHR 4366/4885MAPK1 1100/4885MEN1 1180/4885 |
| US-20250195672-A1 | DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTICS TO NEURONS | GPR119, SLC2A2, SLC2A1 | TSHR 1397/4885MAPK1 2708/4885MEN1 513/4885 |
| US-20190142964-A1 | DENDRIMER DELIVERY SYSTEM AND METHODS OF USE THEREOF | TLR3, CD40LG, OXGR1 | TSHR 2190/4885MAPK1 2303/4885MEN1 3686/4885 |
| US-20260102502-A1 | CANNABINOID DENDRIMER COMPOSITIONS FOR TARGETED DELIVERY | CNR1, CNR2, GPR18 | TSHR 1425/4885MAPK1 2475/4885MEN1 4032/4885 |
| US-20080039547-A1 | Moisture activated latent curing adhesive or sealant | ICAM1, EHMT1, CDH1 | TSHR 4861/4885MAPK1 2967/4885MEN1 1948/4885 |
| US-20080290034-A1 | Bridged macrocyclic module compositions | SBDS, NCL, INTS6 | TSHR 4746/4885MAPK1 3815/4885MEN1 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.